<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle"><p class="DocumentTitle"><strong>CHLORPROMAZINE HYDROCHLORIDE- chlorpromazine hydrochloride tablet, film coated </strong><br>Physicians Total Care, Inc.<br></p></div>
<h1>ChlorproMAZINE Hydrochloride Tablets, USP</h1>
<div class="Contents">
<div class="Section" data-sectionCode="48780-1">
<a name="section-1"></a><p></p>
</div>
<div class="Warning">
<a name="id_59b97d48-127c-48d0-a545-e86ba020be1a"></a><a name="section-1"></a><p></p>
<p class="First"><span class="Bold">WARNING</span></p>
<p><span class="Bold">Increased Mortality in Elderly Patients with <span class="product-label-link" type="condition" conceptid="4182210" conceptname="Dementia">Dementia</span>-Related <span class="product-label-link" type="condition" conceptid="436073" conceptname="Psychotic disorder">Psychosis</span></span></p>
<p><span class="Bold">Elderly patients with <span class="product-label-link" type="condition" conceptid="4182210" conceptname="Dementia">dementia</span>-related <span class="product-label-link" type="condition" conceptid="436073" conceptname="Psychotic disorder">psychosis</span> treated with antipsychotic drugs are at an increased risk of <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span>. Analyses of seventeen placebo-controlled trials (modal duration of 10 weeks), largely in patients taking atypical antipsychotic drugs, revealed a risk of <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span> in drug-treated patients of between 1.6 to 1.7 times the risk of <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span> in placebo-treated patients. Over the course of a typical 10-week controlled trial, the rate of <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span> in drug-treated patients was about 4.5%, compared to a rate of about 2.6% in the placebo group. Although the causes of <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span> were varied, most of the <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">deaths</span> appeared to be either cardiovascular (e.g., <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">heart failure</span>, <span class="product-label-link" type="condition" conceptid="4132309" conceptname="Sudden death">sudden death</span>) or infectious (e.g., <span class="product-label-link" type="condition" conceptid="255848" conceptname="Pneumonia">pneumonia</span>) in nature. Observational studies suggest that, similar to atypical antipsychotic drugs, treatment with conventional antipsychotic drugs may increase mortality. The extent to which the findings of increased mortality in observational studies may be attributed to the antipsychotic drug as opposed to some characteristic(s) of the patients is not clear. Chlorpromazine hydrochloride is not approved for the treatment of patients with <span class="product-label-link" type="condition" conceptid="4182210" conceptname="Dementia">dementia</span>-related <span class="product-label-link" type="condition" conceptid="436073" conceptname="Psychotic disorder">psychosis</span> (see <a href="#i4i_warnings_id_warnings">WARNINGS</a>).</span></p>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="i4i_description_id_144af090-ccc9-4343-ae74-1cc3d7949e80"></a><a name="section-1"></a><p></p>
<h1>DESCRIPTION</h1>
<p class="First">Chlorpromazine hydrochloride, a dimethylamine derivative of phenothiazine, has a chemical formula of 2-chloro-10-[3-(dimethylamino)propyl] phenothiazine monohydrochloride. It is available in tablets for oral administration. It has the following structural formula:</p>
<div class="Figure"><img alt="ChlorproMAZINE Hydrochloride Chemical Structure" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=d2f1cc4b-eaf7-4a76-819e-f5168f22a5de&amp;name=a11a65a4-0352-4b19-be28-9542e3dd8e69-01.jpg"></div>
<p>Chlorpromazine hydrochloride occurs as white or slightly creamy white, odorless, crystalline powder which darkens on prolonged exposure to light.</p>
<p>Each tablet, for oral administration, contains 10, 25, 50, 100, or 200 mg chlorpromazine hydrochloride. Inactive ingredients: D &amp; C Red #30 Aluminum Lake, D &amp; C Yellow #10 Aluminum Lake, FD &amp; C Blue #2 Aluminum Lake, hydroxypropyl cellulose, hydroxypropyl methylcellulose, lactose (monohydrate), magnesium stearate, polyethylene glycol, povidone, starch (corn), and titanium dioxide. The 50, 100, and 200 mg tablets also contain sodium lauryl sulfate.</p>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="i4i_clinical_pharmacology_id_699f8da6-4f4b-4368-ad37-1ede0ff5c445"></a><a name="section-2"></a><p></p>
<h1>CLINICAL PHARMACOLOGY</h1>
<p class="First">The precise mechanism whereby the therapeutic effects of chlorpromazine are produced is not known. The principal pharmacological actions are psychotropic. It also exerts sedative and antiemetic activity. Chlorpromazine has actions at all levels of the central nervous system – primarily at subcortical levels – as well as on multiple organ systems. Chlorpromazine has strong antiadrenergic and weaker peripheral anticholinergic activity; ganglionic blocking action is relatively slight. It also possesses slight antihistaminic and antiserotonin activity.</p>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="i4i_indications_id_36ca8148-863b-45e0-99d5-df456f9bb713"></a><a name="section-3"></a><p></p>
<h1>INDICATIONS AND USAGE</h1>
<p class="First">For the management of manifestations of <span class="product-label-link" type="condition" conceptid="436073" conceptname="Psychotic disorder">psychotic disorders</span>.</p>
<p>For the treatment of <span class="product-label-link" type="condition" conceptid="435783" conceptname="Schizophrenia">schizophrenia</span>.</p>
<p>To control <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span> and <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>.</p>
<p>For relief of <span class="product-label-link" type="condition" conceptid="4012381" conceptname="Restlessness">restlessness</span> and <span class="product-label-link" type="condition" conceptid="441542" conceptname="Anxiety">apprehension</span> before surgery.</p>
<p>For <span class="product-label-link" type="condition" conceptid="4120604" conceptname="Acute intermittent porphyria">acute intermittent porphyria</span>.</p>
<p>As an adjunct in the treatment of <span class="product-label-link" type="condition" conceptid="435740" conceptname="Tetanus">tetanus</span>.</p>
<p>To control the manifestations of the <span class="product-label-link" type="condition" conceptid="4333677" conceptname="Mania">manic</span> type of <span class="product-label-link" type="condition" conceptid="4333677" conceptname="Mania">manic</span>-<span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depressive illness</span>.</p>
<p>For relief of intractable <span class="product-label-link" type="condition" conceptid="194475" conceptname="Hiccoughs">hiccups</span>.</p>
<p>For the treatment of severe behavioral problems in children (1 to 12 years of age) marked by combativeness and/or explosive hyperexcitable behavior (out of proportion to immediate provocations), and in the short-term treatment of <span class="product-label-link" type="condition" conceptid="4137162" conceptname="Overactive">hyperactive</span> children who show excessive motor activity with accompanying <span class="product-label-link" type="condition" conceptid="443617" conceptname="Conduct disorder">conduct disorders</span> consisting of some or all of the following symptoms: impulsivity, difficulty sustaining attention, aggressivity, mood lability and poor <span class="product-label-link" type="condition" conceptid="4074627" conceptname="Feeling frustrated">frustration</span> tolerance.</p>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="i4i_contraindications_id_59147190-a1d6-4c90-8881-20b986a8b06c"></a><a name="section-4"></a><p></p>
<h1>CONTRAINDICATIONS</h1>
<p class="First">Do not use in patients with known <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> to phenothiazines.</p>
<p>Do not use in <span class="product-label-link" type="condition" conceptid="380834" conceptname="Coma">comatose</span> states or in the presence of large amounts of central nervous system depressants (alcohol, barbiturates, narcotics, etc.).</p>
</div>
<div class="Section" data-sectionCode="34071-1">
<a name="i4i_warnings_id_warnings"></a><a name="section-5"></a><p></p>
<h1>WARNINGS</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_984216e5-7206-4761-a441-3d5a9962fdfd"></a><a name="section-5.1"></a><p></p>
<h2>Increased Mortality in Elderly Patients with <span class="product-label-link" type="condition" conceptid="4182210" conceptname="Dementia">Dementia</span>-Related <span class="product-label-link" type="condition" conceptid="436073" conceptname="Psychotic disorder">Psychosis</span></h2>
<p class="First"><span class="Bold">Elderly patients with <span class="product-label-link" type="condition" conceptid="4182210" conceptname="Dementia">dementia</span>-related <span class="product-label-link" type="condition" conceptid="436073" conceptname="Psychotic disorder">psychosis</span> treated with antipsychotic drugs are at an increased risk of <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span>. Chlorpromazine hydrochloride is not approved for the treatment of patients with <span class="product-label-link" type="condition" conceptid="4182210" conceptname="Dementia">dementia</span>-related <span class="product-label-link" type="condition" conceptid="436073" conceptname="Psychotic disorder">psychosis</span> (see <a href="#id_59b97d48-127c-48d0-a545-e86ba020be1a">BOXED WARNING</a>).</span></p>
<p><span class="Bold">The <span class="product-label-link" type="condition" conceptid="373747" conceptname="Extrapyramidal disease">extrapyramidal symptoms</span> which can occur secondary to chlorpromazine may be <span class="product-label-link" type="condition" conceptid="381273" conceptname="Confusional state">confused</span> with the central nervous system signs of an undiagnosed primary disease responsible for the <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>; e.g., Reye's syndrome or other <span class="product-label-link" type="condition" conceptid="372887" conceptname="Disorder of brain">encephalopathy</span>. The use of chlorpromazine and other potential hepatotoxins should be avoided in children and adolescents whose signs and symptoms suggest Reye's syndrome.</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_9fd52dee-6cd4-4706-b1d5-d88ca4a197bb"></a><a name="section-5.2"></a><p></p>
<h2><span class="product-label-link" type="condition" conceptid="4010823" conceptname="Tardive dyskinesia">Tardive Dyskinesia</span></h2>
<p class="First"><span class="product-label-link" type="condition" conceptid="4010823" conceptname="Tardive dyskinesia">Tardive dyskinesia</span>, a syndrome consisting of potentially irreversible, involuntary, dyskinetic movements may develop in patients treated with antipsychotic drugs. Although the prevalence of the syndrome appears to be highest among the elderly, especially elderly women, it is impossible to rely upon prevalence estimates to predict, at the inception of antipsychotic treatment, which patients are likely to develop the syndrome. Whether antipsychotic drug products differ in their potential to cause <span class="product-label-link" type="condition" conceptid="4010823" conceptname="Tardive dyskinesia">tardive dyskinesia</span> is unknown.</p>
<p>Both the risk of developing the syndrome and the likelihood that it will become irreversible are believed to increase as the duration of treatment and the total cumulative dose of antipsychotic drugs administered to the patient increase. However, the syndrome can develop, although much less commonly, after relatively brief treatment periods at low doses.</p>
<p>There is no known treatment for established cases of <span class="product-label-link" type="condition" conceptid="4010823" conceptname="Tardive dyskinesia">tardive dyskinesia</span>, although the syndrome may remit, partially or completely, if antipsychotic treatment is withdrawn. Antipsychotic treatment, itself, however, may suppress (or partially suppress) the signs and symptoms of the syndrome and therapy may possibly mask the underlying disease process. The effect that symptomatic suppression has upon the long-term course of the syndrome is unknown.</p>
<p>Given these considerations, antipsychotics should be prescribed in a manner that is most likely to minimize the occurrence of <span class="product-label-link" type="condition" conceptid="4010823" conceptname="Tardive dyskinesia">tardive dyskinesia</span>. Chronic antipsychotic treatment should generally be reserved for patients who suffer from a chronic illness that, 1.) is known to respond to antipsychotic drugs, and, 2.) for whom alternative, equally effective, but potentially less harmful treatments are <span class="Bold">not </span>available or appropriate. In patients who do require chronic treatment, the smallest dose and the shortest duration of treatment producing a satisfactory clinical response should be sought. The need for continued treatment should be reassessed periodically.</p>
<p>If signs and symptoms of <span class="product-label-link" type="condition" conceptid="4010823" conceptname="Tardive dyskinesia">tardive dyskinesia</span> appear in a patient on antipsychotics, drug discontinuation should be considered. However, some patients may require treatment despite the presence of the syndrome.</p>
<p>For further information about the description of <span class="product-label-link" type="condition" conceptid="4010823" conceptname="Tardive dyskinesia">tardive dyskinesia</span> and its clinical detection, please refer to the sections on <span class="Bold"><a href="#i4i_precautions_id_precautions">PRECAUTIONS</a></span> and <span class="Bold"><a href="#i4i_adverse_effects_id_adverse">ADVERSE REACTIONS</a></span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_e0d12566-eac4-4b78-a917-54a9baa859c1"></a><a name="section-5.3"></a><p></p>
<h2><span class="product-label-link" type="condition" conceptid="379802" conceptname="Neuroleptic malignant syndrome">Neuroleptic Malignant Syndrome</span> (NMS)</h2>
<p class="First">A potentially fatal symptom complex sometimes referred to as <span class="product-label-link" type="condition" conceptid="379802" conceptname="Neuroleptic malignant syndrome">Neuroleptic Malignant Syndrome</span> (NMS) has been reported in association with antipsychotic drugs. Clinical manifestations of NMS are <span class="product-label-link" type="condition" conceptid="4260205" conceptname="Hyperpyrexia">hyperpyrexia</span>, <span class="product-label-link" type="condition" conceptid="4050941" conceptname="Muscle rigidity">muscle rigidity</span>, altered mental status and evidence of <span class="product-label-link" type="condition" conceptid="434633" conceptname="Disorder of autonomic nervous system">autonomic instability</span> (<span class="product-label-link" type="condition" conceptid="4088122" conceptname="Heart irregular">irregular pulse</span> or blood pressure, <span class="product-label-link" type="condition" conceptid="315643" conceptname="Tachyarrhythmia">tachycardia</span>, <span class="product-label-link" type="condition" conceptid="138565" conceptname="Hyperhidrosis">diaphoresis</span>, and <span class="product-label-link" type="condition" conceptid="44784217" conceptname="Cardiac arrhythmia">cardiac dysrhythmias</span>).</p>
<p>The diagnostic evaluation of patients with this syndrome is complicated. In arriving at a diagnosis, it is important to identify cases where the clinical presentation includes both serious medical illness (e.g., <span class="product-label-link" type="condition" conceptid="255848" conceptname="Pneumonia">pneumonia</span>, systemic <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span>, etc.) and untreated or inadequately treated extrapyramidal signs and symptoms (EPS). Other important considerations in the differential diagnosis include central anticholinergic toxicity, <span class="product-label-link" type="condition" conceptid="4181404" conceptname="Heat stroke">heat stroke</span>, <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">drug fever</span> and primary central nervous system (CNS) pathology.</p>
<p>The management of NMS should include 1) immediate discontinuation of antipsychotic drugs and other drugs not essential to concurrent therapy, 2) intensive symptomatic treatment and medical monitoring, and 3) treatment of any concomitant serious medical problems for which specific treatments are available. There is no general agreement about specific pharmacological treatment regimens for uncomplicated NMS.</p>
<p>If a patient requires antipsychotic drug treatment after recovery from NMS, the potential reintroduction of drug therapy should be carefully considered. The patient should be carefully monitored, since recurrences of NMS have been reported.</p>
<p>An encephalopathic syndrome (characterized by <span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">weakness</span>, <span class="product-label-link" type="condition" conceptid="4061577" conceptname="Lethargy">lethargy</span>, <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span>, <span class="product-label-link" type="condition" conceptid="443782" conceptname="Tremor">tremulousness</span> and <span class="product-label-link" type="condition" conceptid="381273" conceptname="Confusional state">confusion</span>, <span class="product-label-link" type="condition" conceptid="373747" conceptname="Extrapyramidal disease">extrapyramidal symptoms</span>, <span class="product-label-link" type="condition" conceptid="438398" conceptname="Leukocytosis">leukocytosis</span>, elevated serum enzymes, BUN and FBS) has occurred in a few patients treated with lithium plus an antipsychotic. In some instances, the syndrome was followed by irreversible <span class="product-label-link" type="condition" conceptid="4080670" conceptname="Brain damage">brain damage</span>. Because of a possible causal relationship between these events and the concomitant administration of lithium and antipsychotics, patients receiving such combined therapy should be monitored closely for early evidence of neurologic toxicity and treatment discontinued promptly if such signs appear. This encephalopathic syndrome may be similar to or the same as <span class="product-label-link" type="condition" conceptid="379802" conceptname="Neuroleptic malignant syndrome">neuroleptic malignant syndrome</span> (NMS).</p>
<p>Patients with <span class="product-label-link" type="condition" conceptid="4145241" conceptname="Bone marrow depression">bone marrow depression</span> or who have previously demonstrated a <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity reaction</span> (e.g., <span class="product-label-link" type="condition" conceptid="40528016" conceptname="Disorder of hematopoietic system">blood dyscrasias</span>, <span class="product-label-link" type="condition" conceptid="137977" conceptname="Jaundice">jaundice</span>) with a phenothiazine should not receive any phenothiazine, including chlorpromazine, unless in the judgment of the physician, the potential benefits of treatment outweigh the possible hazard.</p>
<p>Chlorpromazine may impair mental and/or physical abilities, especially during the first few days of therapy. Therefore, caution patients about activities requiring alertness (e.g., operating vehicles or machinery).</p>
<p>The use of alcohol with this drug should be avoided due to possible additive effects and <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span>.</p>
<p>Chlorpromazine may counteract the antihypertensive effect of guanethidine and related compounds.</p>
</div>
<div class="Section" data-sectionCode="42228-7">
<a name="i4i_pregnancy_id_48214370-5c84-4476-a732-7cc23cb9f34c"></a><a name="section-5.4"></a><p></p>
<h2>Usage In Pregnancy</h2>
<p class="First">Safety for the use of chlorpromazine during pregnancy has not been established. Therefore, it is not recommended that the drug be given to pregnant patients except when, in the judgment of the physician, it is essential. The potential benefits should clearly outweigh possible hazards. There are reported instances of prolonged <span class="product-label-link" type="condition" conceptid="137977" conceptname="Jaundice">jaundice</span>, extrapyramidal signs, <span class="product-label-link" type="condition" conceptid="4313132" conceptname="Hyperreflexia">hyperreflexia</span> or <span class="product-label-link" type="condition" conceptid="4044603" conceptname="Hyporeflexia">hyporeflexia</span> in newborn infants whose mothers received phenothiazines.</p>
<p>Reproductive studies in rodents have demonstrated potential for embryotoxicity, increased neonatal mortality and nursing transfer of the drug. Tests in the offspring of the drug-treated rodents demonstrate decreased performance. The possibility of permanent neurological damage cannot be excluded.</p>
<div class="Section" data-sectionCode="34078-6">
<a name="i4i_non_teratogenic_id_7925c74b-3138-434c-8019-4f57c5c8fdfe"></a><a name="section-5.4.1"></a><p></p>
<h3>Non-teratogenic Effects</h3>
<p class="First">Neonates exposed to antipsychotic drugs, during the third trimester of pregnancy are at risk for extrapyramidal and/or withdrawal symptoms following delivery. There have been reports of <span class="product-label-link" type="condition" conceptid="436087" conceptname="Excitement">agitation</span>, <span class="product-label-link" type="condition" conceptid="4208994" conceptname="Increased muscle tone">hypertonia</span>, <span class="product-label-link" type="condition" conceptid="4002033" conceptname="Muscle relaxation">hypotonia</span>, <span class="product-label-link" type="condition" conceptid="443782" conceptname="Tremor">tremor</span>, <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">somnolence</span>, <span class="product-label-link" type="condition" conceptid="4158346" conceptname="Respiratory distress">respiratory distress</span> and <span class="product-label-link" type="condition" conceptid="434750" conceptname="Feeding difficulties and mismanagement">feeding disorder</span> in these neonates. These complications have varied in severity; while in some cases symptoms have been self-limited, in other cases neonates have required intensive care unit support and prolonged hospitalization.</p>
<p>Chlorpromazine hydrochloride should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.</p>
</div>
</div>
<div class="Section" data-sectionCode="34080-2">
<a name="i4i_nursing_mothers_id_10f14814-86e0-4c0e-850d-ff04168729c8"></a><a name="section-5.5"></a><p></p>
<h2>Nursing Mothers</h2>
<p class="First">There is evidence that chlorpromazine is excreted in the breast milk of nursing mothers. Because of the potential for serious adverse reactions in nursing infants from chlorpromazine, a decision should be made whether to discontinue nursing or to discontinue the drug, taking into account the importance of the drug to the mother.</p>
</div>
</div>
<div class="Section" data-sectionCode="42232-9">
<a name="i4i_precautions_id_precautions"></a><a name="section-6"></a><p></p>
<h1>PRECAUTIONS</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_24257687-e653-452e-a317-fa20ee38d49e"></a><a name="section-6.1"></a><p></p>
<h2><span class="product-label-link" type="condition" conceptid="435224" conceptname="Leukopenia">Leukopenia</span>, <span class="product-label-link" type="condition" conceptid="320073" conceptname="Neutropenia">Neutropenia</span> and <span class="product-label-link" type="condition" conceptid="440689" conceptname="Agranulocytosis">Agranulocytosis</span></h2>
<p class="First">In clinical trial and postmarketing experience, events of <span class="product-label-link" type="condition" conceptid="435224" conceptname="Leukopenia">leukopenia</span>/<span class="product-label-link" type="condition" conceptid="320073" conceptname="Neutropenia">neutropenia</span> and <span class="product-label-link" type="condition" conceptid="440689" conceptname="Agranulocytosis">agranulocytosis</span> have been reported temporally related to antipsychotic agents.</p>
<p>Possible risk factors for <span class="product-label-link" type="condition" conceptid="435224" conceptname="Leukopenia">leukopenia</span>/<span class="product-label-link" type="condition" conceptid="320073" conceptname="Neutropenia">neutropenia</span> include preexisting low white blood cell count (WBC) and history of drug induced <span class="product-label-link" type="condition" conceptid="435224" conceptname="Leukopenia">leukopenia</span>/<span class="product-label-link" type="condition" conceptid="320073" conceptname="Neutropenia">neutropenia</span>. Patients with a preexisting low WBC or a history of drug induced <span class="product-label-link" type="condition" conceptid="435224" conceptname="Leukopenia">leukopenia</span>/<span class="product-label-link" type="condition" conceptid="320073" conceptname="Neutropenia">neutropenia</span> should have their complete blood count (CBC) monitored frequently during the first few months of therapy and should discontinue chlorpromazine hydrochloride tablets USP at the first sign of a decline in WBC in the absence of other causative factors.</p>
<p>Patients with <span class="product-label-link" type="condition" conceptid="320073" conceptname="Neutropenia">neutropenia</span> should be carefully monitored for <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span> or other symptoms or signs of <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> and treated promptly if such symptoms or signs occur. Patients with severe <span class="product-label-link" type="condition" conceptid="320073" conceptname="Neutropenia">neutropenia</span> (absolute neutrophil count &lt;1000/mm<span class="Sup">3</span>) should discontinue chlorpromazine hydrochloride tablets USP and have their WBC followed until recovery.</p>
</div>
<div class="Section" data-sectionCode="34072-9">
<a name="i4i_precautions_general_id_b84cadeb-efda-450a-8818-257639b1e570"></a><a name="section-6.2"></a><p></p>
<h2>General</h2>
<p class="First">Given the likelihood that some patients exposed chronically to antipsychotics will develop <span class="product-label-link" type="condition" conceptid="4010823" conceptname="Tardive dyskinesia">tardive dyskinesia</span>, it is advised that all patients in whom chronic use is contemplated be given, if possible, full information about this risk. The decision to inform patients and/or their guardians must obviously take into account the clinical circumstances and the competency of the patient to understand the information provided.</p>
<p>Chlorpromazine should be administered cautiously to persons with cardiovascular, liver or <span class="product-label-link" type="condition" conceptid="198124" conceptname="Kidney disease">renal disease</span>. There is evidence that patients with a history of <span class="product-label-link" type="condition" conceptid="4029488" conceptname="Hepatic encephalopathy">hepatic encephalopathy</span> due to cirrhosis have increased sensitivity to the CNS effects of chlorpromazine (i.e., impaired cerebration and abnormal slowing of the EEG).</p>
<p>Because of its CNS depressant effect, chlorpromazine should be used with caution in patients with chronic <span class="product-label-link" type="condition" conceptid="320136" conceptname="Disorder of respiratory system">respiratory disorders</span> such as severe <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthma</span>, <span class="product-label-link" type="condition" conceptid="4169883" conceptname="Emphysema">emphysema</span> and acute <span class="product-label-link" type="condition" conceptid="4170143" conceptname="Respiratory tract infection">respiratory infections</span>, particularly in children (1 to 12 years of age).</p>
<p>Because chlorpromazine can suppress the <span class="product-label-link" type="condition" conceptid="254761" conceptname="Cough">cough</span> reflex, <span class="product-label-link" type="condition" conceptid="4239038" conceptname="Pulmonary aspiration">aspiration</span> of vomitus is possible.</p>
<p>Chlorpromazine prolongs and intensifies the action of CNS depressants such as anesthetics, barbiturates and narcotics. When chlorpromazine is administered concomitantly, about 1/4 to 1/2 the usual dosage of such agents is required. When chlorpromazine is not being administered to reduce requirements of CNS depressants, it is best to stop such depressants before starting chlorpromazine treatment. These agents may subsequently be reinstated at low doses and increased as needed.</p>
<p><span class="Bold">Note: </span>Chlorpromazine does <span class="Italics">not</span> intensify the anti-convulsant action of barbiturates. Therefore, dosage of anticonvulsants, including barbiturates, should <span class="Italics">not</span> be reduced if chlorpromazine is started. Instead, start chlorpromazine at low doses and increase as needed.</p>
<p>Use with caution in persons who will be exposed to extreme heat, organophosphorus insecticides, and in persons receiving atropine or related drugs.</p>
<p>Antipsychotic drugs elevate prolactin levels; the elevation persists during chronic administration. Tissue culture experiments indicate that approximately one-third of human breast cancers are prolactin-dependent <span class="Italics">in vitro,</span> a factor of potential importance if the prescribing of these drugs is contemplated in a patient with a previously detected breast cancer. Although disturbances such as <span class="product-label-link" type="condition" conceptid="79884" conceptname="Galactorrhea not associated with childbirth">galactorrhea</span>, <span class="product-label-link" type="condition" conceptid="443800" conceptname="Amenorrhea">amenorrhea</span>, <span class="product-label-link" type="condition" conceptid="4168447" conceptname="Gynecomastia">gynecomastia</span> and <span class="product-label-link" type="condition" conceptid="4216771" conceptname="Impotence">impotence</span> have been reported, the clinical significance of elevated serum prolactin levels is unknown for most patients. An increase in mammary neoplasms has been found in rodents after chronic administration of antipsychotic drugs. Neither clinical nor epidemiologic studies conducted to date, however, have shown an association between chronic administration of these drugs and mammary tumorigenesis; the available evidence is considered too limited to be conclusive at this time.</p>
<p>Chromosomal aberrations in spermatocytes and abnormal sperm have been demonstrated in rodents treated with certain neuroleptics.</p>
<p>As with all drugs which exert an anticholinergic effect, and/or cause <span class="product-label-link" type="condition" conceptid="4290615" conceptname="Dilated pupil">mydriasis</span>, chlorpromazine should be used with caution in patients with <span class="product-label-link" type="condition" conceptid="437541" conceptname="Glaucoma">glaucoma</span>.</p>
<p>Chlorpromazine diminishes the effect of oral anticoagulants.</p>
<p>Phenothiazines can produce alpha-adrenergic blockade.</p>
<p>Chlorpromazine may lower the convulsive threshold; dosage adjustments of anticonvulsants may be necessary. Potentiation of anticonvulsant effects does not occur. However, it has been reported that chlorpromazine may interfere with the metabolism of phenytoin and thus precipitate phenytoin toxicity.</p>
<p>Concomitant administration with propranolol results in increased plasma levels of both drugs.</p>
<p>Thiazide diuretics may accentuate the <span class="product-label-link" type="condition" conceptid="319041" conceptname="Orthostatic hypotension">orthostatic hypotension</span> that may occur with phenothiazines.</p>
<p>The presence of phenothiazines may produce false-positive <span class="product-label-link" type="condition" conceptid="432872" conceptname="Phenylketonuria">phenylketonuria</span> (PKU) test results.</p>
<p>Drugs which lower the <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizure</span> threshold, including phenothiazine derivatives, should not be used with metrizamide. As with other phenothiazine derivatives, chlorpromazine should be discontinued at least 48 hours before myelography, should not be resumed for at least 24 hours postprocedure, and should not be used for the control of <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span> and <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span> occurring either prior to myelography or postprocedure with metrizamide.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_f8e0215b-4d65-44c4-80f7-a8e62c98d7cc"></a><a name="section-6.3"></a><p></p>
<h2>Long-Term Therapy</h2>
<p class="First">To lessen the likelihood of adverse reactions related to cumulative drug effect, patients with a history of long-term therapy with chlorpromazine and/or other antipsychotics should be evaluated periodically to decide whether the maintenance dosage could be lowered or drug therapy discontinued.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_ef8af4f6-b6f2-456f-b3a0-306974703c56"></a><a name="section-6.4"></a><p></p>
<h2>Antiemetic Effect</h2>
<p class="First">The antiemetic action of chlorpromazine may mask the signs and symptoms of overdosage of other drugs and may obscure the diagnosis and treatment of other conditions such as <span class="product-label-link" type="condition" conceptid="193518" conceptname="Intestinal obstruction">intestinal obstruction</span>, <span class="product-label-link" type="condition" conceptid="4116092" conceptname="Intracranial tumor">brain tumor</span> and Reye's syndrome. (See <span class="Bold"><a href="#i4i_warnings_id_warnings">WARNINGS</a></span>.)</p>
<p>When chlorpromazine is used with cancer chemotherapeutic drugs, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span> as a sign of the toxicity of these agents may be obscured by the antiemetic effect of chlorpromazine.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_2e461c91-5857-4e69-8e10-a1eb2afedb44"></a><a name="section-6.5"></a><p></p>
<h2>Abrupt Withdrawal</h2>
<p class="First">Like other phenothiazines, chlorpromazine is not known to cause psychic <span class="product-label-link" type="condition" conceptid="4113279" conceptname="Dependence">dependence</span> and does not produce tolerance or addiction. There may be, however, following abrupt withdrawal of high-dose therapy, some symptoms resembling those of physical <span class="product-label-link" type="condition" conceptid="4113279" conceptname="Dependence">dependence</span> such as <span class="product-label-link" type="condition" conceptid="201340" conceptname="Gastritis">gastritis</span>, <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span> and <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span> and <span class="product-label-link" type="condition" conceptid="443782" conceptname="Tremor">tremulousness</span>. These symptoms can usually be avoided or reduced by gradual reduction of the dosage or by continuing concomitant anti-<span class="product-label-link" type="condition" conceptid="4140090" conceptname="Parkinsonism">parkinsonism</span> agents for several weeks after chlorpromazine is withdrawn.</p>
</div>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="i4i_adverse_effects_id_adverse"></a><a name="section-7"></a><p></p>
<h1>ADVERSE REACTIONS</h1>
<p class="First"><span class="Bold">Note:</span> Some adverse effects of chlorpromazine may be more likely to occur, or occur with greater intensity, in patients with special medical problems; e.g., patients with <span class="product-label-link" type="condition" conceptid="443962" conceptname="Mitral valve regurgitation">mitral insufficiency</span> or <span class="product-label-link" type="condition" conceptid="4118993" conceptname="Pheochromocytoma">pheochromocytoma</span> have experienced severe <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span> following recommended doses.</p>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_fab00da4-712c-48a0-853a-feabc8a4d311"></a><a name="section-7.1"></a><p></p>
<h2><span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">Drowsiness</span></h2>
<p class="First">Usually mild to moderate may occur, particularly during the first or second week, after which it generally disappears. If troublesome, dosage may be lowered.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_925203b9-8c61-4169-8235-92ba5dbff8e4"></a><a name="section-7.2"></a><p></p>
<h2><span class="product-label-link" type="condition" conceptid="137977" conceptname="Jaundice">Jaundice</span></h2>
<p class="First">Overall incidence has been low, regardless of indication or dosage. Most investigators conclude it is a sensitivity reaction. Most cases occur between the second and fourth weeks of therapy. The clinical picture resembles <span class="product-label-link" type="condition" conceptid="4223947" conceptname="Viral hepatitis, type A">infectious hepatitis</span>, with laboratory features of <span class="product-label-link" type="condition" conceptid="4185719" conceptname="Cholestatic jaundice syndrome">obstructive jaundice</span>, rather than those of parenchymal damage. It is usually promptly reversible on withdrawal of the medication; however, chronic <span class="product-label-link" type="condition" conceptid="137977" conceptname="Jaundice">jaundice</span> has been reported.</p>
<p>There is no conclusive evidence that preexisting liver disease makes patients more susceptible to <span class="product-label-link" type="condition" conceptid="137977" conceptname="Jaundice">jaundice</span>. Alcoholics with cirrhosis have been successfully treated with chlorpromazine without complications. Nevertheless, the medication should be used cautiously in patients with liver disease. Patients who have experienced <span class="product-label-link" type="condition" conceptid="137977" conceptname="Jaundice">jaundice</span> with a phenothiazine should not, if possible, be reexposed to chlorpromazine or other phenothiazines.</p>
<p>If <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span> with grippe-like symptoms occurs, appropriate liver studies should be conducted. If tests indicate an abnormality, stop treatment.</p>
<p>Liver function tests in <span class="product-label-link" type="condition" conceptid="137977" conceptname="Jaundice">jaundice</span> induced by the drug may mimic extrahepatic obstruction; withhold exploratory laparotomy until extrahepatic obstruction is confirmed.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_40fc5b88-54f8-4335-a868-7ebbee91ed46"></a><a name="section-7.3"></a><p></p>
<h2>Hematologic Disorders</h2>
<p class="First">Including <span class="product-label-link" type="condition" conceptid="440689" conceptname="Agranulocytosis">agranulocytosis</span>, <span class="product-label-link" type="condition" conceptid="4302954" conceptname="Disorder characterized by eosinophilia">eosinophilia</span>, <span class="product-label-link" type="condition" conceptid="435224" conceptname="Leukopenia">leukopenia</span>, <span class="product-label-link" type="condition" conceptid="435503" conceptname="Hemolytic anemia">hemolytic anemia</span>, <span class="product-label-link" type="condition" conceptid="137829" conceptname="Aplastic anemia">aplastic anemia</span>, <span class="product-label-link" type="condition" conceptid="4119134" conceptname="Thrombocytopenic purpura">thrombocytopenic purpura</span> and <span class="product-label-link" type="condition" conceptid="432881" conceptname="Pancytopenia">pancytopenia</span> have been reported.</p>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_30c4829e-40ff-4e7e-b3d0-12ca9aa43b3d"></a><a name="section-7.3.1"></a><p></p>
<h3><span class="product-label-link" type="condition" conceptid="440689" conceptname="Agranulocytosis">Agranulocytosis</span></h3>
<p class="First">Warn patients to report the sudden appearance of <span class="product-label-link" type="condition" conceptid="26711" conceptname="Chronic pharyngitis">sore throat</span> or other signs of <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span>. If white blood cell and differential counts indicate cellular <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span>, stop treatment and start antibiotic and other suitable therapy.</p>
<p>Most cases have occurred between the 4th and 10th weeks of therapy; patients should be watched closely during that period.</p>
<p>Moderate suppression of white blood cells is not an indication for stopping treatment unless accompanied by the symptoms described above.</p>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_c2efa065-8ae3-4d07-b30b-74d2f8c1535f"></a><a name="section-7.4"></a><p></p>
<h2>Cardiovascular</h2>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_3fad059d-84b6-450a-8f1b-22dbca70e03d"></a><a name="section-7.4.1"></a><p></p>
<h3>Hypotensive Effects</h3>
<p class="First"><span class="product-label-link" type="condition" conceptid="319041" conceptname="Orthostatic hypotension">Postural hypotension</span>, simple <span class="product-label-link" type="condition" conceptid="315643" conceptname="Tachyarrhythmia">tachycardia</span>, momentary <span class="product-label-link" type="condition" conceptid="135360" conceptname="Syncope">fainting</span> and <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span> may occur rarely, after the first oral dose. Usually recovery is spontaneous and symptoms disappear within 1/2 to 2 hours. Occasionally, these effects may be more severe and prolonged, producing a <span class="product-label-link" type="condition" conceptid="201965" conceptname="Shock">shock</span>-like condition.</p>
<p>To control <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span>, place patient in head-low position with legs raised. If a vasoconstrictor is required, norepinephrine and phenylephrine are the most suitable. Other pressor agents, including epinephrine, should not be used as they may cause a paradoxical further lowering of blood pressure.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_532e04b9-f362-4e16-8016-95f4ddf6eef5"></a><a name="section-7.4.2"></a><p></p>
<h3>EKG Changes</h3>
<p class="First">Particularly nonspecific, usually reversible Q and T wave distortions – have been observed in some patients receiving phenothiazine tranquilizers, including chlorpromazine.</p>
<p><span class="Bold">Note: </span><span class="product-label-link" type="condition" conceptid="4132309" conceptname="Sudden death">Sudden death</span>, apparently due to <span class="product-label-link" type="condition" conceptid="321042" conceptname="Cardiac arrest">cardiac arrest</span>, has been reported.</p>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_5318e077-3946-4999-8338-8127fd3a0a96"></a><a name="section-7.5"></a><p></p>
<h2>CNS Reactions</h2>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_7126c307-7711-4b3f-9d6f-c2e2c36c6324"></a><a name="section-7.5.1"></a><p></p>
<h3><span class="product-label-link" type="condition" conceptid="373747" conceptname="Extrapyramidal disease">Extrapyramidal Symptoms</span></h3>
<p class="First">Neuromuscular reactions include <span class="product-label-link" type="condition" conceptid="375800" conceptname="Dystonia">dystonias</span>, <span class="product-label-link" type="condition" conceptid="4012381" conceptname="Restlessness">motor restlessness</span>, pseudo-<span class="product-label-link" type="condition" conceptid="4140090" conceptname="Parkinsonism">parkinsonism</span> and <span class="product-label-link" type="condition" conceptid="4010823" conceptname="Tardive dyskinesia">tardive dyskinesia</span>, and appear to be dose-related. They are discussed in the following paragraphs:</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_6bcdcdbc-2d08-47ea-bec2-ff92f25257ff"></a><a name="section-7.5.2"></a><p></p>
<h3><span class="product-label-link" type="condition" conceptid="375800" conceptname="Dystonia">Dystonia</span></h3>
<p class="First"><span class="Italics">Class effect:</span>  Symptoms of <span class="product-label-link" type="condition" conceptid="375800" conceptname="Dystonia">dystonia</span>, prolonged abnormal contractions of muscle groups, may occur in susceptible individuals during the first few days of treatment. Dystonic symptoms include: spasm of the neck muscles, sometimes progressing to tightness of the throat, swallowing difficulty, <span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">difficulty breathing</span>, and/or protrusion of the tongue. While these symptoms can occur at low doses, they occur more frequently and with greater severity with high potency and at higher doses of first generation antipsychotic drugs. An elevated risk of <span class="product-label-link" type="condition" conceptid="375800" conceptname="Dystonia">acute dystonia</span> is observed in males and younger age groups.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_a2be03e5-4ffd-4f02-9c27-90c1b6ebaaa9"></a><a name="section-7.5.3"></a><p></p>
<h3><span class="product-label-link" type="condition" conceptid="4012381" conceptname="Restlessness">Motor Restlessness</span></h3>
<p class="First">Symptoms may include <span class="product-label-link" type="condition" conceptid="436087" conceptname="Excitement">agitation</span> or <span class="product-label-link" type="condition" conceptid="436817" conceptname="Feeling nervous">jitteriness</span> and sometimes <span class="product-label-link" type="condition" conceptid="436962" conceptname="Insomnia">insomnia</span>. These symptoms often disappear spontaneously. At times, these symptoms may be similar to the original neurotic or <span class="product-label-link" type="condition" conceptid="436073" conceptname="Psychotic disorder">psychotic</span> symptoms. Dosage should not be increased until these side effects have subsided.</p>
<p>If these symptoms become too troublesome, they can usually be controlled by a reduction of dosage or change of drug. Treatment with anti-parkinsonian agents, benzodiazepines or propranolol may be helpful.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_014f336c-63be-4bcc-a5b5-4a358a86d891"></a><a name="section-7.5.4"></a><p></p>
<h3>Pseudo-<span class="product-label-link" type="condition" conceptid="4140090" conceptname="Parkinsonism">parkinsonism</span></h3>
<p class="First">Symptoms may include: mask-like facies, <span class="product-label-link" type="condition" conceptid="4266842" conceptname="Dribbling from mouth">drooling</span>, <span class="product-label-link" type="condition" conceptid="443782" conceptname="Tremor">tremors</span>, pillrolling motion, <span class="product-label-link" type="condition" conceptid="4208094" conceptname="Cogwheel muscle rigidity">cogwheel rigidity</span> and shuffling gait. In most cases, these symptoms are readily controlled when an anti-<span class="product-label-link" type="condition" conceptid="4140090" conceptname="Parkinsonism">parkinsonism</span> agent is administered concomitantly. Anti-<span class="product-label-link" type="condition" conceptid="4140090" conceptname="Parkinsonism">parkinsonism</span> agents should be used only when required. Generally, therapy of a few weeks to 2 or 3 months will suffice. After this time patients should be evaluated to determine their need for continued treatment. (<span class="Bold">Note: </span>Levodopa has not been found effective in antipsychotic-induced pseudo-<span class="product-label-link" type="condition" conceptid="4140090" conceptname="Parkinsonism">parkinsonism</span>.) Occasionally, it is necessary to lower the dosage of chlorpromazine or to discontinue the drug. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_5f441784-9749-4d19-a37b-10b954a11711"></a><a name="section-7.5.5"></a><p></p>
<h3><span class="product-label-link" type="condition" conceptid="4010823" conceptname="Tardive dyskinesia">Tardive Dyskinesia</span></h3>
<p class="First">As with all antipsychotic agents, <span class="product-label-link" type="condition" conceptid="4010823" conceptname="Tardive dyskinesia">tardive dyskinesia</span> may appear in some patients on long-term therapy or may appear after drug therapy has been discontinued. The syndrome can also develop, although much less frequently, after relatively brief treatment periods at low doses. This syndrome appears in all age groups. Although its prevalence appears to be highest among elderly patients, especially elderly women, it is impossible to rely upon prevalence estimates to predict at the inception of antipsychotic treatment which patients are likely to develop the syndrome. The symptoms are persistent and in some patients appear to be irreversible. The syndrome is characterized by rhythmical involuntary movements of the tongue, face, mouth or jaw (e.g., protrusion of tongue, puffing of cheeks, puckering of mouth, chewing movements). Sometimes these may be accompanied by involuntary movements of extremities. In rare instances, these involuntary movements of the extremities are the only manifestations of <span class="product-label-link" type="condition" conceptid="4010823" conceptname="Tardive dyskinesia">tardive dyskinesia</span>. A variant of <span class="product-label-link" type="condition" conceptid="4010823" conceptname="Tardive dyskinesia">tardive dyskinesia</span>, tardive <span class="product-label-link" type="condition" conceptid="375800" conceptname="Dystonia">dystonia</span>, has also been described.</p>
<p>There is no known effective treatment for <span class="product-label-link" type="condition" conceptid="4010823" conceptname="Tardive dyskinesia">tardive dyskinesia</span>; anti-<span class="product-label-link" type="condition" conceptid="4140090" conceptname="Parkinsonism">parkinsonism</span> agents do not alleviate the symptoms of this syndrome. If clinically feasible, it is suggested that all antipsychotic agents be discontinued if these symptoms appear. Should it be necessary to reinstitute treatment, or increase the dosage of the agent, or switch to a different antipsychotic agent, the syndrome may be masked.</p>
<p>It has been reported that fine vermicular movements of the tongue may be an early sign of the syndrome and if the medication is stopped at that time, the syndrome may not develop.</p>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_20fafb68-8d8c-4567-a79b-9c5946392570"></a><a name="section-7.6"></a><p></p>
<h2>Adverse Behavioral Effects</h2>
<p class="First"><span class="product-label-link" type="condition" conceptid="436073" conceptname="Psychotic disorder">Psychotic</span> symptoms and <span class="product-label-link" type="condition" conceptid="4085823" conceptname="Catatonia">catatonic</span>-like states have been reported rarely.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_fa11eec4-49a7-4abe-999a-ecd532dbc8c3"></a><a name="section-7.7"></a><p></p>
<h2>Other CNS Effects</h2>
<p class="First"><span class="product-label-link" type="condition" conceptid="379802" conceptname="Neuroleptic malignant syndrome">Neuroleptic Malignant Syndrome</span> (NMS) has been reported in association with antipsychotic drugs. (See <span class="Bold"><a href="#i4i_warnings_id_warnings">WARNINGS</a></span>.)</p>
<p><span class="product-label-link" type="condition" conceptid="376690" conceptname="Cerebral edema">Cerebral edema</span> has been reported.</p>
<p><span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">Convulsive seizures</span> (<span class="Bold"><span class="product-label-link" type="condition" conceptid="4194232" conceptname="Absence seizure">petit mal</span></span> and <span class="Bold"><span class="product-label-link" type="condition" conceptid="374924" conceptname="Generalized convulsive epilepsy">grand mal</span></span>) have been reported, particularly in patients with EEG abnormalities or history of such disorders.</p>
<p>Abnormality of the <span class="product-label-link" type="condition" conceptid="4222478" conceptname="Measurement of protein in cerebrospinal fluid specimen">cerebrospinal fluid proteins</span> has also been reported. <span class="Bold"><span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Allergic Reactions</span> </span>of a mild urticarial type or <span class="product-label-link" type="condition" conceptid="4080920" conceptname="Phytophotodermatitis">photosensitivity</span> are seen. Avoid undue exposure to sun. More severe reactions, including <span class="product-label-link" type="condition" conceptid="4270887" conceptname="Erythroderma">exfoliative dermatitis</span>, have been reported occasionally.</p>
<p><span class="product-label-link" type="condition" conceptid="134438" conceptname="Contact dermatitis">Contact dermatitis</span> has been reported in nursing personnel; accordingly, the use of rubber gloves when administering chlorpromazine liquid or injectable is recommended.</p>
<p>In addition, <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthma</span>, <span class="product-label-link" type="condition" conceptid="22350" conceptname="Edema of larynx">laryngeal edema</span>, <span class="product-label-link" type="condition" conceptid="432791" conceptname="Angioedema">angioneurotic edema</span> and <span class="product-label-link" type="condition" conceptid="4148381" conceptname="Anaphylactoid reaction">anaphylactoid reactions</span> have been reported.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_b5f7531d-1ef7-464c-989f-d0c857715110"></a><a name="section-7.8"></a><p></p>
<h2><span class="product-label-link" type="condition" conceptid="31821" conceptname="Disorder of endocrine system">Endocrine Disorders</span></h2>
<p class="First">Lactation and moderate <span class="product-label-link" type="condition" conceptid="80478" conceptname="Engorgement of breasts associated with childbirth">breast engorgement</span> may occur in females on large doses. If persistent, lower dosage or withdraw drug. False-<span class="product-label-link" type="condition" conceptid="4094910" conceptname="Pregnancy test positive">positive pregnancy tests</span> have been reported, but are less likely to occur when a serum test is used. <span class="product-label-link" type="condition" conceptid="443800" conceptname="Amenorrhea">Amenorrhea</span> and <span class="product-label-link" type="condition" conceptid="4168447" conceptname="Gynecomastia">gynecomastia</span> have also been reported. <span class="product-label-link" type="condition" conceptid="4214376" conceptname="Hyperglycemia">Hyperglycemia</span>, <span class="product-label-link" type="condition" conceptid="24609" conceptname="Hypoglycemia">hypoglycemia</span> and <span class="product-label-link" type="condition" conceptid="434164" conceptname="Glycosuria">glycosuria</span> have been reported.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_6da2baf5-3116-4fad-b992-60845e15084d"></a><a name="section-7.9"></a><p></p>
<h2>Autonomic Reactions</h2>
<p class="First">Occasional <span class="product-label-link" type="condition" conceptid="4226991" conceptname="Aptyalism">dry mouth</span>; <span class="product-label-link" type="condition" conceptid="4195085" conceptname="Nasal congestion">nasal congestion</span>; <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>; <span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">obstipation</span>; <span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">constipation</span>; <span class="product-label-link" type="condition" conceptid="192357" conceptname="Paralytic ileus">adynamic ileus</span>; <span class="product-label-link" type="condition" conceptid="192450" conceptname="Retention of urine">urinary retention</span>, <span class="product-label-link" type="condition" conceptid="315586" conceptname="Priapism">priapism</span>, <span class="product-label-link" type="condition" conceptid="435279" conceptname="Tonic pupillary reaction">miosis</span> and <span class="product-label-link" type="condition" conceptid="4290615" conceptname="Dilated pupil">mydriasis</span>, atonic colon, ejaculatory disorders/<span class="product-label-link" type="condition" conceptid="4216771" conceptname="Impotence">impotence</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_c0d7df19-6d75-4142-9d63-066e974a6ba7"></a><a name="section-7.10"></a><p></p>
<h2>Special Consideration in Long-Term Therapy</h2>
<p class="First"><span class="product-label-link" type="condition" conceptid="4083855" conceptname="Abnormal pigment">Skin pigmentation</span> and ocular changes have occurred in some patients taking substantial doses of chlorpromazine for <span class="product-label-link" type="condition" conceptid="4088438" conceptname="Prolonged periods">prolonged periods</span>.</p>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_1381bd22-b421-49c0-9d83-de32c23e9147"></a><a name="section-7.10.1"></a><p></p>
<h3><span class="product-label-link" type="condition" conceptid="4083855" conceptname="Abnormal pigment">Skin Pigmentation</span></h3>
<p class="First">Rare instances of <span class="product-label-link" type="condition" conceptid="4083855" conceptname="Abnormal pigment">skin pigmentation</span> have been observed in hospitalized mental patients, primarily females who have received the drug usually for 3 years or more in dosages ranging from 500 mg to 1500 mg daily. The pigmentary changes, restricted to exposed areas of the body, range from an almost imperceptible darkening of the skin to a slate gray color, sometimes with a violet hue. Histological examination reveals a pigment, chiefly in the dermis, which is probably a melanin-like complex. The <span class="product-label-link" type="condition" conceptid="4083855" conceptname="Abnormal pigment">pigmentation</span> may fade following discontinuance of the drug.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_ab72904d-3fff-4f73-b999-6ac2873f6ffd"></a><a name="section-7.10.2"></a><p></p>
<h3>Ocular Changes</h3>
<p class="First">Ocular changes have occurred more frequently than <span class="product-label-link" type="condition" conceptid="4083855" conceptname="Abnormal pigment">skin pigmentation</span> and have been observed both in pigmented and nonpigmented patients receiving chlorpromazine, usually for 2 years or more in dosages of 300 mg daily and higher. Eye changes are characterized by deposition of fine particulate matter in the lens and cornea. In more advanced cases, star-shaped opacities have also been observed in the anterior portion of the lens. The nature of the eye deposits has not yet been determined. A small number of patients with more severe ocular changes have had some <span class="product-label-link" type="condition" conceptid="373786" conceptname="Abnormal vision">visual impairment</span>. In addition to these corneal and lenticular changes, epithelial <span class="product-label-link" type="condition" conceptid="436695" conceptname="Band-shaped keratopathy">keratopathy</span> and pigmentary <span class="product-label-link" type="condition" conceptid="376103" conceptname="Retinopathy">retinopathy</span> have been reported. Reports suggest that the eye lesions may regress after withdrawal of the drug.</p>
<p>Since the occurrence of eye changes seems to be related to dosage levels and/or duration of therapy, it is suggested that long-term patients on moderate to high dosage levels have periodic ocular examinations.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_23cac2f6-9e4c-4d48-9783-5d5d84c42e80"></a><a name="section-7.10.3"></a><p></p>
<h3>Etiology</h3>
<p class="First">The etiology of both of these reactions is not clear, but exposure to light, along with dosage/duration of therapy, appears to be the most significant factor. If either of these reactions is observed, the physician should weigh the benefits of continued therapy against the possible risks and, on the merits of the individual case, determine whether or not to continue present therapy, lower the dosage, or withdraw the drug.</p>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_67d65114-2b8c-42f9-84d6-6c354208df0b"></a><a name="section-7.11"></a><p></p>
<h2>Other Adverse Reactions</h2>
<p class="First">Mild <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span> may occur after large I.M. doses. <span class="product-label-link" type="condition" conceptid="4260205" conceptname="Hyperpyrexia">Hyperpyrexia</span> has been reported. Increases in appetite and weight sometimes occur. <span class="product-label-link" type="condition" conceptid="4094513" conceptname="Ankle edema">Peripheral edema</span> and a <span class="product-label-link" type="condition" conceptid="257628" conceptname="Systemic lupus erythematosus">systemic lupus erythematosus</span>-like syndrome have been reported.</p>
<p><span class="Bold">Note: </span>There have been occasional reports of <span class="product-label-link" type="condition" conceptid="4132309" conceptname="Sudden death">sudden death</span> in patients receiving phenothiazines. In some cases, the cause appeared to be <span class="product-label-link" type="condition" conceptid="321042" conceptname="Cardiac arrest">cardiac arrest</span> or <span class="product-label-link" type="condition" conceptid="4139960" conceptname="Strangulation">asphyxia</span> due to failure of the <span class="product-label-link" type="condition" conceptid="254761" conceptname="Cough">cough</span> reflex..</p>
</div>
</div>
<div class="Section" data-sectionCode="34088-5">
<a name="i4i_overdosage_id_d589fd20-4358-4445-a2ed-505992fc8049"></a><a name="section-8"></a><p></p>
<h1>OVERDOSAGE</h1>
<p class="First">(See also <span class="Bold"><a href="#i4i_adverse_effects_id_adverse">ADVERSE REACTIONS</a></span>.)</p>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_da13285a-0c0b-4c44-b36b-3d65e986bf99"></a><a name="section-8.1"></a><p></p>
<h2>Symptoms</h2>
<p class="First">Primarily symptoms of central nervous system <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span> to the point of <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">somnolence</span> or <span class="product-label-link" type="condition" conceptid="380834" conceptname="Coma">coma</span>.</p>
<p><span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">Hypotension</span> and <span class="product-label-link" type="condition" conceptid="373747" conceptname="Extrapyramidal disease">extrapyramidal symptoms</span>.</p>
<p>Other possible manifestations include <span class="product-label-link" type="condition" conceptid="436087" conceptname="Excitement">agitation</span> and <span class="product-label-link" type="condition" conceptid="4012381" conceptname="Restlessness">restlessness</span>, <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">convulsions</span>, <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span>, autonomic reactions such as <span class="product-label-link" type="condition" conceptid="4226991" conceptname="Aptyalism">dry mouth</span> and <span class="product-label-link" type="condition" conceptid="193518" conceptname="Intestinal obstruction">ileus</span>. EKG changes and <span class="product-label-link" type="condition" conceptid="44784217" conceptname="Cardiac arrhythmia">cardiac arrhythmias</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_d6b82610-d807-476a-8b5b-7eeeab9f43bc"></a><a name="section-8.2"></a><p></p>
<h2>Treatment</h2>
<p class="First">It is important to determine other medications taken by the patient since multiple drug therapy is common in overdosage situations. Treatment is essentially symptomatic and supportive. Early gastric lavage is helpful. Keep patient under observation and maintain an open airway, since involvement of the extrapyramidal mechanism may produce <span class="product-label-link" type="condition" conceptid="31317" conceptname="Dysphagia">dysphagia</span> and respiratory difficulty in severe overdosage. <span class="Bold">Do not attempt to induce <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">emesis</span> because a <span class="product-label-link" type="condition" conceptid="375800" conceptname="Dystonia">dystonic reaction</span> of the head or neck may develop that could result in <span class="product-label-link" type="condition" conceptid="4239038" conceptname="Pulmonary aspiration">aspiration</span> of vomitus. </span><span class="product-label-link" type="condition" conceptid="373747" conceptname="Extrapyramidal disease">Extrapyramidal symptoms</span> may be treated with anti-<span class="product-label-link" type="condition" conceptid="4140090" conceptname="Parkinsonism">parkinsonism</span> drugs, barbiturates, or diphenhydramine hydrochloride. See prescribing information for these products. Care should be taken to avoid increasing <span class="product-label-link" type="condition" conceptid="4214898" conceptname="Decreased respiratory function">respiratory depression</span>.</p>
<p>If administration of a stimulant is desirable, amphetamine, dextroamphetamine, or caffeine with sodium benzoate is recommended. Stimulants that may cause <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">convulsions</span> (e.g., picrotoxin or pentylenetetrazol) should be avoided.</p>
<p>If <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span> occurs, the standard measures for managing circulatory <span class="product-label-link" type="condition" conceptid="201965" conceptname="Shock">shock</span> should be initiated. If it is desirable to administer a vasoconstrictor, norepinephrine and phenylephrine are most suitable. Other pressor agents, including epinephrine, are not recommended because phenothiazine derivatives may reverse the usual elevating action of these agents and cause a further lowering of blood pressure.</p>
<p>Limited experience indicates that phenothiazines are <span class="Bold">not </span>dialyzable.</p>
</div>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="i4i_dosage_admin_id_de69806b-f16c-4636-a22b-7658d21205c3"></a><a name="section-9"></a><p></p>
<h1>DOSAGE AND ADMINISTRATION</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_f67f87c5-2d90-4c46-ae25-e0f83146b622"></a><a name="section-9.1"></a><p></p>
<h2>Adults</h2>
<p class="First">Adjust dosage to individual and the severity of his condition, recognizing that the milligram for milligram potency relationship among all dosage forms has not been precisely established clinically. It is important to increase dosage until symptoms are controlled. Dosage should be increased more gradually in debilitated or emaciated patients. In continued therapy, gradually reduce dosage to the lowest effective maintenance level, after symptoms have been controlled for a reasonable period.</p>
<p>The 100 mg and 200 mg tablets are for use in severe neuropsychiatric conditions.</p>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_7331195c-e289-4e47-8de8-368aa876e652"></a><a name="section-9.1.1"></a><p></p>
<h3>Elderly Patients</h3>
<p class="First">In general, dosages in the lower range are sufficient for most elderly patients. Since they appear to be more susceptible to <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span> and neuromuscular reactions, such patients should be observed closely. Dosage should be tailored to the individual, response carefully monitored, and dosage adjusted accordingly. Dosage should be increased more gradually in elderly patients.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_5f79652f-3c49-403c-9e33-fcbaaf291ebb"></a><a name="section-9.1.2"></a><p></p>
<h3><span class="product-label-link" type="condition" conceptid="436073" conceptname="Psychotic disorder">Psychotic Disorders</span></h3>
<p class="First">Increase dosage gradually until symptoms are controlled. Maximum improvement may not be seen for weeks or even months. Continue optimum dosage for 2 weeks; then gradually reduce dosage to the lowest effective maintenance level. Daily dosage of 200 mg is not unusual. Some patients require higher dosages (e.g., 800 mg daily is not uncommon in discharged mental patients).</p>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_9124d767-ef84-410a-beae-eeab2b0cc3c9"></a><a name="section-9.1.2.1"></a><p></p>
<h4>Hospitalized Patients</h4>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_3198f36e-99c6-443d-816f-06bcb6858aae"></a><a name="section-9.1.2.1.1"></a><p></p>
<h5>Acute Schizophrenic or <span class="product-label-link" type="condition" conceptid="4333677" conceptname="Mania">Manic States</span></h5>
<p class="First">It is recommended that initial treatment be with chlorpromazine injection until patient is controlled. Usually patient becomes quiet and cooperative within 24 to 48 hours and oral doses may be substituted and increased until the patient is calm. 500 mg a day is generally sufficient. While gradual increases to 2000 mg a day or more may be necessary, there is usually little therapeutic gain to be achieved by exceeding 1000 mg a day for extended periods. In general, dosage levels should be lower in the elderly, the emaciated and the debilitated.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_93015573-1bdc-46d0-9a1b-2fb4fadf4bb9"></a><a name="section-9.1.2.1.2"></a><p></p>
<h5>Less Acutely Disturbed</h5>
<p class="First">25 mg t.i.d. Increased gradually until effective dose is reached - usually 400 mg daily.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_774ec9d0-bb13-4328-bad6-cf7bcededfa7"></a><a name="section-9.1.2.1.3"></a><p></p>
<h5>Outpatients</h5>
<p class="First">10 mg t.i.d. or q.i.d., or 25 mg b.i.d. or t.i.d.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_4ad29293-97d0-47d9-8358-fe86b0d4feeb"></a><a name="section-9.1.2.1.4"></a><p></p>
<h5>More Severe Cases</h5>
<p class="First">25 mg t.i.d. After 1 or 2 days, daily dosage may be increased by 20 to 50 mg at semi-weekly intervals until patient becomes calm and cooperative.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_fbda895a-6a14-4e10-a2d5-d6da3ec7dc87"></a><a name="section-9.1.2.1.5"></a><p></p>
<h5>Prompt Control of Severe Symptoms</h5>
<p class="First">Initial treatment should be with intramuscular chlorpromazine. Subsequent doses should be oral, 25 to 50 mg t.i.d.</p>
</div>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_1f74d331-1eb5-4c8b-a457-d47dde97704f"></a><a name="section-9.1.3"></a><p></p>
<h3><span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">Nausea</span> and <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">Vomiting</span></h3>
<p class="First">10 to 25 mg q4 to 6h, p.r.n., increased, if necessary.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_b166d065-7148-4cce-8661-7c9db8796e35"></a><a name="section-9.1.4"></a><p></p>
<h3>Presurgical <span class="product-label-link" type="condition" conceptid="441542" conceptname="Anxiety">Apprehension</span></h3>
<p class="First">25 to 50 mg, 2 to 3 hours before the operation.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_71daa65c-3699-465a-b8c8-f3c16e2efb0e"></a><a name="section-9.1.5"></a><p></p>
<h3>Intractable <span class="product-label-link" type="condition" conceptid="194475" conceptname="Hiccoughs">Hiccups</span></h3>
<p class="First">25 to 50 mg t.i.d. or q.i.d. If symptoms persist for 2 to 3 days, parenteral therapy is indicated.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_d1dd3d32-aacf-42e2-a2c7-7adcdf005c0a"></a><a name="section-9.1.6"></a><p></p>
<h3><span class="product-label-link" type="condition" conceptid="4120604" conceptname="Acute intermittent porphyria">Acute Intermittent Porphyria</span></h3>
<p class="First">25 to 50 mg t.i.d. or q.i.d. Can usually be discontinued after several weeks, but maintenance therapy may be necessary for some patients.</p>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_d3a1acde-786c-47d0-b5a0-e864c0f701f2"></a><a name="section-9.2"></a><p></p>
<h2>Pediatric Patients (6 months to 12 years of age)</h2>
<p class="First">Chlorpromazine should generally not be used in pediatric patients under 6 months of age except where potentially lifesaving. It should not be used in conditions for which specific pediatric dosages have not been established.</p>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_8d4bccf5-06d3-46f3-8e14-d938884f418e"></a><a name="section-9.2.1"></a><p></p>
<h3>Severe Behavioral Problems</h3>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_f014fbce-0a29-4f29-b1c4-4aba90f38643"></a><a name="section-9.2.1.1"></a><p></p>
<h4>Outpatients</h4>
<p class="First">Select route of administration according to severity of patient's condition and increase dosage gradually as required. Oral: 1/4 mg/lb body weight q4 to 6h, p.r.n. (e.g., for 40 lb child - 10 mg q4 to 6h).</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_1b570705-929e-4c58-94ac-3440fc6f1958"></a><a name="section-9.2.1.2"></a><p></p>
<h4>Hospitalized Patients</h4>
<p class="First">As with outpatients, start with low doses and increase dosage gradually. In severe behavior disorders higher dosages (50 to 100 mg daily and in older children, 200 mg daily or more) may be necessary. There is little evidence that behavior improvement in severely disturbed mentally retarded patients is further enhanced by doses beyond 500 mg per day.</p>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_6b078ee2-d37b-4eb9-afe4-5655c6ec3334"></a><a name="section-9.2.2"></a><p></p>
<h3><span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">Nausea</span> and <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">Vomiting</span></h3>
<p class="First">Dosage and frequency of administration should be adjusted according to the severity of the symptoms and response of the patient. The duration of activity following intramuscular administration may last up to 12 hours. Subsequent doses may be given by the same route if necessary. Oral: 1/4 mg/lb body weight (e.g., 40 lb child - 10 mg q4 to 6h).</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_6c2f0c8b-ac53-4a18-b4b4-b69f166e4aae"></a><a name="section-9.2.3"></a><p></p>
<h3>Presurgical <span class="product-label-link" type="condition" conceptid="441542" conceptname="Anxiety">Apprehension</span></h3>
<p class="First">1/4 mg/lb body weight orally 2 to 3 hours before operation.</p>
</div>
</div>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="i4i_how_supplied_id_8de30b52-b379-4848-b900-55dd6db0a2d7"></a><a name="section-10"></a><p></p>
<h1>HOW SUPPLIED</h1>
<p class="First">Chlorpromazine hydrochloride tablets, USP are available as:</p>
<br><p><span class="Bold">25 mg: </span>Round, film-coated, butterscotch colored tablets, debossed GG 476 on one side and 25 on the reverse side, and supplied as:</p>
<a name="ia4f59e0a-b250-41d3-869d-ef22c8cd9441"></a><table width="30%"><tbody class="Headless"><tr class="First Last">
<td>Bottles of 30<br>
</td>
<td>NDC 54868-2464-0<br>
</td>
</tr></tbody></table>
<br><div class="Section" data-sectionCode="44425-7">
<a name="i4i_storage_id_4a51dc25-78d6-470c-bef5-780d0388a403"></a><a name="section-10.1"></a><p></p>
<p class="First">Store at 20°-25°C (68°-77°F) (see USP Controlled Room Temperature). Protect from moisture.</p>
<p>Dispense in a tight, light-resistant container.</p>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_c736128b-c13e-4c89-9055-545eeabe473c"></a><a name="section-11"></a><p></p>
<p class="First">03-2011M</p>
<p>7192</p>
<p>Sandoz Inc.</p>
<p>Princeton, NJ 08540</p>
<div class="Section" data-sectionCode="42229-5">
<a name="section-11.1"></a><p></p>
<p class="First">Distributed by:<br>Physicians Total Care, Inc.<br>Tulsa, Oklahoma        74146<br></p>
</div>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="i4i_Principal_display_panel_id_51fb6dcb-22e2-40e9-a626-180756b8d873"></a><a name="section-12"></a><p></p>
<h1></h1>
<p class="First"><img alt="Chlorpromazine Hydrochloride 25 mg Label" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=d2f1cc4b-eaf7-4a76-819e-f5168f22a5de&amp;name=2464.jpg"></p>
<p>ChlorproMAZINE</p>
<p>Hydrochloride</p>
<p>Tablets, USP</p>
<p>25 mg</p>
<p>Rx only</p>
<br>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>CHLORPROMAZINE HYDROCHLORIDE 		
					</strong><br><span class="contentTableReg">chlorpromazine hydrochloride tablet, film coated</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:54868-2464(NDC:0781-1716)</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">ORAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>CHLORPROMAZINE HYDROCHLORIDE</strong> (CHLORPROMAZINE) </td>
<td class="formItem">CHLORPROMAZINE HYDROCHLORIDE</td>
<td class="formItem">25 mg</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>D&amp;C RED NO. 30</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>D&amp;C YELLOW NO. 10</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>FD&amp;C BLUE NO. 2</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>HYDROXYPROPYL CELLULOSE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>HYPROMELLOSES</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>LACTOSE MONOHYDRATE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>MAGNESIUM STEARATE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>POLYETHYLENE GLYCOLS</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>POVIDONE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>STARCH, CORN</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>TITANIUM DIOXIDE</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Characteristics</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">ORANGE (butterscotch) </td>
<td class="formLabel">Score</td>
<td class="formItem">no score</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem">ROUND</td>
<td class="formLabel">Size</td>
<td class="formItem">8mm</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem"></td>
<td class="formLabel">Imprint Code</td>
<td class="formItem">GG476;25</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem">    </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:54868-2464-0</td>
<td class="formItem">30  in 1 BOTTLE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">ANDA</td>
<td class="formItem">ANDA080439</td>
<td class="formItem">01/03/1973</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler - </span>Physicians Total Care, Inc.
							(194123980)
						</td></tr></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Establishment</span></td></tr>
<tr>
<th scope="col" class="formTitle">Name</th>
<th scope="col" class="formTitle">Address</th>
<th scope="col" class="formTitle">ID/FEI</th>
<th scope="col" class="formTitle">Business Operations</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">Physicians Total Care, Inc.</td>
<td class="formItem"></td>
<td class="formItem">194123980</td>
<td class="formItem">relabel(54868-2464), repack(54868-2464)</td>
</tr>
</table>
</div>
<p><div class="EffectiveDate">Revised: 3/2013<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>ead4d3e2-ae16-4381-a78c-0c4bbd225b3c</div>
<div>Set id: d2f1cc4b-eaf7-4a76-819e-f5168f22a5de</div>
<div>Version: 1</div>
<div>Effective Time: 20130304</div>
</div>
</div> <div class="DistributorName">Physicians Total Care, Inc.</div></p>
</body></html>
